Lp(a): a basic clinical approach with Dr. Steven Nissen Part 1 of 2
Feb 13, 2024
auto_awesome
Dr. Steven Nissen, the Chief Academic Officer at the Cleveland Clinic and a leading expert in cardiology, joins Dr. Thomas Nero to discuss the critical role of lipoprotein(a) in cardiovascular disease. They emphasize the necessity of routine testing for Lp(a), particularly for those with family histories of heart disease. The conversation includes challenges in lowering Lp(a) levels, the limitations of current treatments, and insights into ongoing clinical trials for drugs like pellicarsin. Real patient scenarios highlight aggressive strategies for managing elevated LDL post-myocardial infarction.
Routine screening for lipoprotein(a) is essential for early detection of cardiovascular risk, especially for those with a family history.
Current research is exploring therapies to lower lipoprotein(a) levels, emphasizing individualized treatment approaches based on patient risk factors.
Deep dives
Understanding Lipoprotein(a) and Its Risks
Lipoprotein(a) is a type of cholesterol particle that significantly increases the risk of developing coronary artery disease, being more atherogenic than LDL cholesterol. Levels exceeding 70 milligrams per deciliter heighten the risk of cardiovascular disease, potentially doubling or tripling it. In particular, elevated levels of lipoprotein(a) contribute to both atherosclerosis and thrombosis, which are critical factors in heart disease. Therefore, it is crucial for individuals to know their lipoprotein(a) levels, especially if they have a family history of coronary heart disease.
Current Screening and Management Recommendations
Routine screening for lipoprotein(a) is recommended for everyone at least once in their lifetime, ideally in their early 20s if there's a family history of heart disease. Although no current treatments directly lower lipoprotein(a) levels, managing other risk factors can delay the onset of cardiovascular issues. Patients should focus on controlling blood pressure, maintaining a healthy weight, exercising regularly, and achieving low LDL cholesterol levels. These lifestyle and medical interventions can help mitigate overall cardiovascular risk despite the presence of elevated lipoprotein(a).
Future Therapies and Guidelines Adjustments
Ongoing clinical trials aim to explore potential therapies for reducing lipoprotein(a) levels, with some results anticipated by 2025. Current guidelines advocate aggressive management of patients with elevated lipoprotein(a), stressing the need for lower LDL cholesterol goals and potential use of injectable agents like PCSK9 inhibitors. Individualized treatment plans may involve higher intensity statin therapies along with other lipid-lowering medications, depending on the patient’s history and risk factors. It is acknowledged that guidelines serve as suggestions rather than strict mandates, allowing clinicians to tailor treatment strategies for their patients.
Dr Steven Nissen from the Cleveland Clinic discuses with Dr. Thomas Nero the basic clinical approach to Lp(a) with need for routine testing and a few simple case studies. In the second (longer podcast) they take a deep deep dive into Lp(a) genetic, pathophysiology and the current research trials.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode